Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6421
    -0.0005 (-0.08%)
     

  • OIL

    83.30
    +0.57 (+0.69%)
     

  • GOLD

    2,409.00
    +11.00 (+0.46%)
     

  • Bitcoin AUD

    100,276.27
    +1,676.22 (+1.70%)
     

  • CMC Crypto 200

    1,382.49
    +69.87 (+5.32%)
     

  • AUD/EUR

    0.6025
    -0.0006 (-0.10%)
     

  • AUD/NZD

    1.0904
    +0.0029 (+0.27%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,028.28
    -366.03 (-2.10%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,940.69
    +165.31 (+0.44%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Why Shares of Ocular Therapeutix Jumped This Week

Jim Halley, The Motley Fool
·2-min read
Why Shares of Ocular Therapeutix Jumped This Week

Shares of Ocular Therapeutix (NASDAQ: OCUL) were up by 49.6% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The biopharmaceutical company specializes in finding therapies to treat diseases and conditions of the eye. The healthcare company, on Feb. 11, announced preliminary 10-month data on its phase 1 trial of OTX-TKI, an axitinib (a small molecule, multitarget, tyrosine kinase inhibitor) intravitreal (inside the eye) hydrogel implant to treat age-related macular degeneration (AMD), diabetic retinopathy and other diseases of the retina.

Continue reading